Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same author

Host metabolism can produce many indoles and phenols independently of the microbiome.

Nature metabolism·2026
Same author

Leveraging 13C-Labeling to Assign Molecular Formulas to Unknown Yeast Metabolites.

Journal of the American Society for Mass Spectrometry·2026
Same author

A Liver-Targeted Copper Supplement Reduces Metabolic Dysfunction-Associated Liver Steatosis by Increasing Lipolysis and Fatty Acid Oxidation.

bioRxiv : the preprint server for biology·2026
Same author

Monocyte infiltration induces CNS arginine catabolism to fuel neuroinflammation.

Nature immunology·2026
Same author

Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias.

Cancer discovery·2026

関連する実験動画

Updated: Sep 8, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K

PAX3-FOXO1は,ラブドミオサルコムの標的細胞状態に依存する代謝的脆弱性を誘発する.

Katrina I Paras1, Julia S Brunner1, Angela M Montero1

  • 1Memorial Sloan Kettering Cancer Center, New York, United States.

Cancer research
|September 5, 2025
PubMed
まとめ
この要約は機械生成です。

PAX3- FOXO1によって引き起こされる攻撃的なラブドミオサルコマ (RMS) は,ピリミジン合成への依存度が増加しています. メソトレクサートによる二酸化葉酸還元酵素 (DHFR) 標的治療は,これらの小児腫瘍に対する新たな治療の可能性を提供します.

さらに関連する動画

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

関連する実験動画

Last Updated: Sep 8, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

科学分野:

  • 腫瘍学
  • 分子生物学
  • 生物化学

背景:

  • PAX3- FOXO1は攻撃的なリブドミオサルコマ (RMS) の主要な原動力である.
  • 悪性細胞はしばしば 代謝経路が変化して 急速な成長を促します
  • RMSサブタイプの特定の代謝依存性を理解することは,標的治療に不可欠です.

研究 の 目的:

  • PAX3-FOXO1によるRMSの代謝変化を調査する.
  • これらの代謝変化に関連した潜在的な治療的脆弱性を特定する.
  • PAX3- FOXO1+ RMSにおけるピリミジン合成の標的化の有効性を評価する.

主な方法:

  • PAX3-FOXO1+ RMS細胞における遺伝子発現と代謝経路の分析
  • デヒドロフォラート還元酵素 (DHFR) 阻害に対する細胞の感受性の評価
  • ピリミジンヌクレオチドによる救出実験
  • PAX3- FOXO1+と融合陰性RMS異種移植モデルを用いたインビボ試験

主要な成果:

  • PAX3- FOXO1+ RMS細胞は,DHFRを含むデノボ合成への依存度が増加したピリミジン代謝を示す.
  • これらの細胞はメソトレクサートによるDHFR阻害に敏感であり,ピリミジンヌクレオチドによって救出することができます.
  • メソトレクサート治療はPAX3- FOXO1静止の代謝および転写効果を再現します.
  • メソトレクサートはPAX3- FOXO1+ RMSの異種移植では腫瘍の成長を著しく遅らせたが,融合陰性RMSではそうではなかった.

結論:

  • PAX3- FOXO1 腫瘍因子はRMSにおけるピリミジン依存状態を誘発する.
  • メソトレクサートによるDHFR阻害は,PAX3- FOXO1- 誘発性ラブドミオサルコムの有望な治療戦略です.
  • メソトレクサートは,これらの侵襲的な小児腫瘍の治療法に 価値ある追加となる可能性があります.